ID: ALA222717

Max Phase: Preclinical

Molecular Formula: C24H16O4

Molecular Weight: 368.39

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(c1ccccc1)c1ccc(-c2ccc(-c3ccc(C(=O)O)o3)cc2)cc1

Standard InChI:  InChI=1S/C24H16O4/c25-23(19-4-2-1-3-5-19)20-12-8-17(9-13-20)16-6-10-18(11-7-16)21-14-15-22(28-21)24(26)27/h1-15H,(H,26,27)

Standard InChI Key:  UKLDRYNCWUIPPD-UHFFFAOYSA-N

Associated Targets(non-human)

Creatine kinase M-type 22 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 368.39Molecular Weight (Monoisotopic): 368.1049AlogP: 5.54#Rotatable Bonds: 5
Polar Surface Area: 67.51Molecular Species: ACIDHBA: 3HBD: 1
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.14CX Basic pKa: CX LogP: 5.36CX LogD: 1.91
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.47Np Likeness Score: -0.39

References

1. Bretonnet AS, Jochum A, Walker O, Krimm I, Goekjian P, Marcillat O, Lancelin JM..  (2007)  NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site.,  50  (8): [PMID:17375903] [10.1021/jm061460r]

Source